Cancer Biology & Medicine

►►Submit your paper by clicking the ABOVE RED TAG "ONLINE SUBMISSION".

 

►►Very important notification on publication fee

Effective February 2019, Cancer Biology & Medicine, as an open access journal, will charge a reasonable publication fee of $1,500/¥10,000 for each accepted article (all article types). No fees will be charged for invited articles.


Cancer Biology & Medicine

Cancer Biology & Medicine is a peer-reviewed open-access journal published by the China Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Published quarterly, the journal provides innovative and significant information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:

● Cancer genetics

● Cancer and stem cell biology

● Molecular and clinical immunology

● Cancer prevention and epidemiology

● Cancer biomarkers

● Radiation oncology

● Oncology clinical trials

● Mechanisms of drug sensitivity and resistance

● Targeted therapy and immunotherapy

● Multidisciplinary treatment and personalized medicine

Author Benefits

● Professional and precise peer review

● Efficient and high-quality service

● International visibility and open access

● Large audience of CACA members

 

 

Announcements

 

New impact factor: 4.248

 

According to the Journal Citation Reports, the Impact Factor (2020) of Cancer Biology & Medicine is 4.248.

As a peer-reviewed open-access journal, Cancer Biology & Medicine is quarterly published by China Anti-Cancer Association and Tianjin Medical University Cancer Institute and Hospital. It focuses on translational cancer research, dedicating to narrowing the gap between bench and bedside. Except for SCIE, the journal has been indexed in MEDLINE, PubMed/ PubMed Central, BIOSIS Previews, SCOPUS, DOAJ, and Chemical Abstracts. Meanwhile, it is also a member of the Committee on Publication Ethics (COPE) and CrossRef.

Welcome to submit your work to Cancer Biology & Medicine and communicate with your colleagues worldwide via our platform.

 
Posted: 2021-07-01
 

Publication of the 2nd issue in 2021

 

In this issue, five reviews focus on cancer nano-medicine, including stimuli-responsive nanocarriers, nanotechnology-based theranostic systems, delivery vehicles related to vaccine development, gold-based nanomaterials in brain cancer treatment, and nanotechnology in overcoming drug resistance. Meanwhile, two reviews on circular RNA's role in chemoresistance and its potential clinical application are specially recommended.

Of the original articles, Prof. Cortesi Laura from University Hospital of Modena (Italy) evaluated the BRCA mutation rate in families with prostate cancer (PrC) associated with breast and/or ovarian cancers, and compared the characteristics of families and BRCA-related PrC outcome; Prof. Jie He from Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College indicated a correlation between treatment-induced hypertension and better prognoses in recurrent or metastatic esophageal squamous cell carcinoma patients treated with anlotinib. We hope the issue will greatly benefit your research and clinical practice. Welcome to submit your work to Cancer Biology & Medicine.

 
Posted: 2021-05-14
 
More Announcements...

Vol 18, No 3: August 2021

Table of Contents

Editorial

A breakthrough in liver regeneration for treatment of liver cancer PDF
Hao Xu, et al. 631-634

Review

Current research on circular RNAs and their potential clinical implications in breast cancer PDF
Diya Liu, et al. 635-648
Strategies to enhance monoclonal antibody uptake and distribution in solid tumors PDF
Brandon M. Bordeau, et al. 649-664

Original Article

FGFR/RACK1 interacts with MDM2, promotes P53 degradation, and inhibits cell senescence in lung squamous cell carcinoma PDF
Tao Chen, et al. 665-674
LncRNA DPP10-AS1 promotes malignant processes through epigenetically activating its cognate gene DPP10 and predicts poor prognosis in lung cancer patients PDF
Haihua Tian, et al. 675-692
Heat shock protein 90 promotes RNA helicase DDX5 accumulation and exacerbates hepatocellular carcinoma by inhibiting autophagy PDF
Ting Zhang, et al. 693-704
NEDD9 promotes cancer stemness by recruiting myeloidderived suppressor cells via CXCL8 in esophageal squamous cell carcinoma PDF
Dongli Yue,et al. 705-720
Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma PDF
Fengjuan Jiang, et al. 721-733
A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma PDF
Chengming Liu, et al. 734-749
Raltitrexed as a synergistic hyperthermia chemotherapy drug screened in patient-derived colorectal cancer organoids PDF
Lisi Zeng, et al. 750-762
Development and validation of a risk model for noninvasive detection of cancer in oral potentially malignant disorders using DNA image cytometry PDF
Chenxi Li, et al. 763-771
VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo PDF
Guangbo Kang, et al. 772-787
CD44v8-10 is a marker for malignant traits and a potential driver of bone metastasis in a subpopulation of prostate cancer cells PDF
Rosaria A. Fontanella, et al. 788-807
Typing of biliary tumor thrombus influences the prognoses of patients with hepatocellular carcinoma PDF
Juxian Sun, et al. 808-815
Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial PDF
Tianqing Chu, et al. 816-824
Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies PDF
Winnie Yeo, et al. 825-832
Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma PDF
Meiting Chen, et al. 833-840
The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study PDF
Wei Zhang, et al. 841-848
Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer PDF
Nanlin Hu, et al. 849-859
Transcription factor-based gene therapy to treat glioblastoma through direct neuronal conversion PDF
Xin Wang, et al. 860-874
Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA PDF
Anjie Zhu, et al. 875-887
Epstein-Barr virus DNA loads in the peripheral blood cells predict the survival of locoregionally-advanced nasopharyngeal carcinoma patients PDF
Yongqiao He, et al. 888-899
Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030 PDF
Shaoyuan Lei, et al. 900-909
Efficacy of the new therapeutic approach in curing malignant neoplasms on the model of human glioblastoma PDF
Evgeniya V. Dolgova, et al. 910-930


OUR FRIENDS